Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Net Cash Flow data on file, last reported at $60.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 53.46% year-over-year to $60.7 million; the trailing twelve-month figure through Mar 2026 stood at $676.4 million (up 105.72% YoY), and the FY2025 full-year result was $655.2 million, up 287.69% from the prior year.
• Net Cash Flow for Q1 2026 stood at $60.7 million, down from $171.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $495.6 million in Q3 2022 and bottomed at -$283.7 million in Q1 2022.
• The 5-year median for Net Cash Flow is $50.3 million (2022), against an average of $51.7 million.
• The widest annual swing landed in 2022, when Net Cash Flow plunged 150.73%; it then surged 2124.43% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$208.5 million in 2022, then fell by 10.92% to -$231.2 million in 2023, then jumped by 49.58% to -$116.6 million in 2024, then soared by 247.29% to $171.7 million in 2025, then tumbled by 64.66% to $60.7 million in 2026.
• The last three Net Cash Flow figures came in at $60.7 million (Q1 2026), $171.7 million (Q4 2025), and $377.9 million (Q3 2025), per Business Quant data.

Peer Comparison